Author:
Liu Na,Wang Xiaohong,Zhu Jixiang,Basu Sumit,Wei Yudong,Yan Bei,Wang Hui,Colon-Gonzalez Francheska,Feng Hwa-Ping,Sun Fang,Li Haiyan,Zang Yanqiao
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine
Reference29 articles.
1. Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf; 2019. [accessed 17 February 2022].
2. World Health Organization (WHO). Global action plan on antimicrobial resistance, https://www.amcra.be/swfiles/files/WHO%20actieplan_90.pdf; 2015. [accessed 17 February 2022].
3. China's national plan to combat antimicrobial resistance;Xiao;Lancet Infect Dis,2016
4. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers;Carvalhaes;Diagn Microbiol Infect Dis,2019
5. In vitro comparison of ceftolozane-tazobactam to traditional beta-lactams and ceftolozane-tazobactam as an alternative to combination antimicrobial therapy for Pseudomonas aeruginosa;Goodlet;Antimicrob Agents Chemother,2017